Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.

@article{Gonzalez2008ExpansionOC,
  title={Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.},
  author={V. D. Gonzalez and K. Falconer and J. Micha{\"e}lsson and Markus Moll and O. Reichard and A. Alaeus and J. K. Sandberg},
  journal={Clinical immunology},
  year={2008},
  volume={128 1},
  pages={
          46-56
        }
}
  • V. D. Gonzalez, K. Falconer, +4 authors J. K. Sandberg
  • Published 2008
  • Biology, Medicine
  • Clinical immunology
  • Co-infection with HCV and HIV-1 is a problem of increasing importance and the role of innate cellular immunity in this co-infection is incompletely understood. Here, we have observed sharply elevated numbers of CD56(-)CD16(+) perforin(low) NK cells in HCV/HIV-1 co-infected subjects on antiretroviral therapy. Interestingly, this expansion of unconventional CD56(-) NK cells rapidly reverted when HCV was suppressed by IFNalpha and ribavirin treatment, and was not seen in mono-infected control… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    The purpose of this study is to investigate T-cell mediated immune responses to HIV-1 and HCV and determine how these responses are affected by HCV treatment and correlates to response… Expand
    ConditionsChronic Hepatitis C, Human Immunodeficiency Virus
    InterventionDrug
    Innate and adaptive cellular immunity in chronic HCV and HIV-1 infection

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 64 REFERENCES